After surgery inside the uterus, the raw inner walls can heal together and form scar tissue, known as intrauterine adhesions or, when symptoms follow, Asherman syndrome. A gel made of hyaluronic acid is one way of trying to keep those walls apart while they heal. Here is what trials have found so far, including where they disagree.
Why adhesions form, and why they come back
Most adhesions follow a curettage (D&C) after miscarriage or delivery. Infection and other operations inside the uterus are less common causes. Periods may become very light or stop, and conceiving or carrying a pregnancy can become harder.
Treatment means separating the scars under direct vision with a hysteroscope, a thin camera passed through the cervix. The international AAGL/ESGE guideline considers this the standard approach and advises against blind curettage for adhesions. The difficulty comes afterwards: the guideline reports recurrence in 30% to 66% of treated women, and in about two thirds of severe cases.
What the gel is meant to do
Hyaluronic acid occurs naturally in the body. Placed in the uterus at the end of surgery, the gel acts as a temporary barrier between the walls. Standard forms break down fairly quickly, so manufacturers have developed cross-linked versions that stay in place longer.
The AAGL/ESGE guideline states that hyaluronic acid gel reduces recurrence, and that its effect on later pregnancy is unknown. Research published since then has mostly filled in the first half of that sentence.
What the trials show
- Fewer adhesions overall. A 2024 analysis in the American Journal of Obstetrics & Gynecology pooled 16 randomised trials and 2,359 patients. Adhesions were about half as frequent with the gel (risk ratio 0.53).
- After curettage. In the French HYFACO trial, adhesions were found in 9.1% of women who received the gel and 18.4% of those who did not.
- Greater benefit against moderate and severe adhesions. A 2022 meta-analysis of randomised trials saw a clear reduction in these, and no effect on mild adhesions.
Where the evidence is less clear
Pregnancy. The 2024 analysis found somewhat higher pregnancy rates with the gel (risk ratio 1.24), but its authors judged the pregnancy and live birth findings inconclusive. HYFACO found no difference in pregnancy at 12 months. Fewer scars do not automatically mean more babies, and no gel can promise a pregnancy.
Women who already have Asherman syndrome. Most of the strongest data come from surgery for other reasons. When adhesions have already been treated and the aim is to stop them returning, results are mixed: a 2023 review did not find a significant reduction (risk ratio 0.80), and a 2024 network meta-analysis found no difference in recurrence of moderate to severe adhesions. Follow-up remains essential whichever gel is used.
Which gel, and how much. A 2021 network meta-analysis suggested that cross-linked hyaluronic acid, with or without an intrauterine device, ranked among the most effective options, but it could not name one clear best method. Analyses also disagree on volume: one found volumes under 5 mL ineffective, another reported benefit with small volumes. A dose that suits everyone has not been established.
Safety. The 2024 analysis concluded that the gel is safe to use, and a multicentre randomised trial of an auto-cross-linked gel recorded no adverse effects among 82 treated women. These numbers are reassuring, though still modest for detecting rare problems.
Hyaluronic acid gel and repeated implantation failure
A small study from Belgium, published in 2025, followed 20 women with repeated implantation failure and changes in the junctional zone on MRI. They had a hysteroscopic procedure on the uterine wall followed by a cross-linked gel containing the steroid budesonide. Pregnancy outcomes were encouraging, yet there was no comparison group, and the authors themselves state that cause and effect cannot be concluded or the contribution of each step separated. This is early research. It is not established care, and controlled trials are needed.
What this means if you have adhesions
Gel is one part of a plan. Hormone treatment may be added to help the lining heal, and the guideline recommends checking the cavity, preferably by hysteroscopy, after two to three menstrual cycles. In severe cases more than one procedure may be needed. A pregnancy after treatment needs close follow-up, because abnormal attachment of the placenta is more common.
Whether gel suits you depends on the cause and extent of your adhesions and on your plans for pregnancy, so this is a decision to make with your doctor. You can read more about hysteroscopy.
Sources: AAGL/ESGE practice guideline on intrauterine adhesions, 2017 (doi) · Luo et al., Am J Obstet Gynecol 2024 (doi) · HYFACO trial, Am J Obstet Gynecol 2022 (doi) · Liu et al., Complement Ther Clin Pract 2022 (doi) · Guo et al., Hum Fertil 2023 (doi) · Tang et al., Arch Gynecol Obstet 2024 (doi) · Vitale et al., Am J Obstet Gynecol 2021 (doi) · J Minim Invasive Gynecol 2022 (doi) · Chen et al., Ann Transl Med 2022 (doi) · Facts Views Vis Obgyn 2025 (doi). This article is for general education and does not replace a medical consultation. Written with AI assistance under the medical supervision of Assist. Prof. Dr. Muzaffer Uçarer (Obstetrics & Gynaecology · IVF and Reproductive Medicine), UCARER Women’s Health, Istanbul.
